Astrazeneca Ab

Astra Aktiebolag

Sverker Hanson

Gunnar Nordvall

Lars George Johansson

Daniel Dungan Sohn

There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R, R, R, R, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

Thioxanthine derivatives as myeloperoxidase inhibitors

Provided herein is a compound having the formula (Ia): wherein said compounds are useful for the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease and pain.

[object Object]

A process for the manufacture of the racemic compound of the formula (I), its R-enantiomer (formula R-(I)) and its S-enantiomer (formula S-(I)),

Growing community of inventors

Sodertalje, Sweden

Sverker Hanson